$PSNL

Tempus AI (NASDAQ: TEM) shares rose about 12.6% in a weekly update after a $1.5B Personalis deal. The article cites strong AI healthcare adoption, gross margin of 73.5%, revenue around $1.27B, but negative EBIT margin of -14.4%. It highlights technical support near $47 and resistance around $55-$57.

Personalis (PSNL) reported Q2 2026 revenue of $22.36M, up from $17.20M a year earlier, but net loss widened to $31.68M and basic loss per share rose to $0.30 from $0.23. For H1 2026, revenue was about $37.83M, flat, while net loss grew to $61.72M. The company reaffirmed 2026 guidance of $78.0–80.0M revenue and about $105M net loss.

Personalis (Nasdaq: PSNL) reported Q2 2026 results for the quarter ended June 30. Clinical tests rose 199% to 10,384. Clinical revenue increased 442% to $2.6 million, while total revenue grew 30% to $22.4 million. The company said it secured Medicare coverage for NeXT Personal in additional IO and neoadjuvant breast cancer indications and ended the quarter with about $212.7 million in cash.

Personalis, Inc. (PSNL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 psnl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Personalis Reports Second Quarter Results and Recent Highlights Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2 Clinical revenue grew 442% to $2.6 million and overall revenue grew 30

TipRanks reports that Tempus AI, Inc. Class A (TEM) disclosed risks tied to its proposed acquisition of Personalis. It says integration complexity, higher costs, and possible regulatory scrutiny could reduce the ability to achieve expected synergies. TipRanks also cites an average TEM price target of $65.77, implying 49.92% upside.

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

Tempus AI (TEM) shares were discussed after Needham reiterated a buy rating and set a $75 price target. The Personalis acquisition was cited by market observers as a long-term catalyst in the MRD space. The stock reportedly gapped lower, with support near $48 to $44 and risk if it breaks below $31. Q1 2026 revenue was $348.1M, up 36.12% YoY.

Tempus AI (TEM) agreed to acquire Personalis (PSNL) for about $1.5 billion, paying $16.25 per Personalis share including debt. The deal gives Tempus full control of the NeXT Personal MRD cancer test. Personalis reported preliminary Q2 revenue of $22.4 million. Tempus stock fell about 9% on July 20 amid expected dilution and delayed closing to late 2026/early 2027.

Tempus AI (NASDAQ:TEM) agreed to acquire Personalis (NASDAQ:PSNL) for $1.5 billion to expand minimal residual disease (MRD) capabilities. Tempus shares recovered after an early selloff. William Blair sees strategic fit and a $20 billion MRD market, but notes a high ~14x 2027 sales multiple and Personalis’ expected 2027 adjusted EBITDA loss of about $90 million. BNP Paribas said the deal could increase pressure on Natera (NASDAQ:NTRA).

The article says President Trump plans 100% tariffs on generic drugs starting August 2028, rising to 200% in 2029, with analysts warning this could raise costs since most generics are made overseas. It also covers a cyclosporiasis outbreak, and Tempus’ planned $1.5B acquisition of Personalis, noting Tempus shares down 7% and Personalis down 13%.